aBLA Filing Intelligence & Biosimilar Opportunity

Bizengri

Zenocutuzumab-Zbco

Immunomodulators

Injection

Bizengri is an IV antibody therapy for adults with advanced non-small cell lung cancer or pancreatic cancer driven by NRG1 gene fusions, used after standard treatments fail. It blocks the fusion protein’s signaling to help shrink tumors and control disease progression

Approval Date

04-Dec-24

Data Exclusivity Expiry

04-Dec-28

Market Exclusivity Expiry

04-Dec-36

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

2028

2029

2030

2031

2032

Molecule profile

Details & specifications

Molecule

Zenocutuzumab-Zbco

Innovator

MERUS N.V.

Dosage Form

Injection

Strength

375 mg/18.75 mL

Therapeutic Category

Immunomodulators

Usage

To treat non-small cell lung cancer and pancreatic adenocarcinoma

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets